Antiplatelet therapy for the primary and secondary prevention of cerebrovascular events in patients with extracranial carotid artery disease

Journal of Vascular Surgery

Volumn 50, Issue 2, 2009, Pages 431-439

  Kiernan, Thomas J ^a   Yan, Bryan P ^a   Jaff, Michael R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; CLOPIDOGREL PLUS ACETYLSALICYLIC ACID; DEXTRAN; DIPYRIDAMOLE; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ANTIHYPERTENSIVE THERAPY; BLEEDING; BLOOD PRESSURE; BRAIN EMBOLISM; CAROTID ENDARTERECTOMY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; INTERNAL CAROTID ARTERY OCCLUSION; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVASCULARIZATION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; STENT; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGE FACTORS; CAROTID ARTERY DISEASES; CEREBROVASCULAR DISORDERS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK FACTORS; SECONDARY PREVENTION;

EID: 67651064993     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2009.04.052     Document Type: Review

References (86)

1. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2005), American Heart Association, Dallas, Tex
2. Prati P., Vanuzzo D., Casaroli M., Di Chiara A., De Biasi F., Feruglio G.A., and Touboul P.J. Prevalence and determinants of carotid atherosclerosis in a general population. Stroke 23 (1992) 1705-1711
3. O'Leary D.H., Polak J.F., Kronmal R.A., Kittner S.J., Bond M.G., Wolfson Jr. S.K., et al. Distribution and correlates of sonographically detected carotid artery disease in the cardiovascular health study. The CHS collaborative research group. Stroke 23 (1992) 1752-1760
4. Ricci S., Flamini F.O., and Celani M.G. Prevalence of internal carotid artery stenosis in subjects older than 49 years: a population study. Cerebrovasc Dis 1 (1991) 16-19
5. Norris J.W., Zhu C.Z., Bornstein N.M., and Chambers B.R. Vascular risks of asymptomatic carotid stenosis. Stroke 22 (1991) 1485-1490
6. Inzitari D., Eliasziw M., Gates P., Sharpe B.L., Chan R.K., Meldrum H.E., and Barnett H.J. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 342 (2000) 1693-1700
7. Barnett H.J., Gunton R.W., Eliasziw M., Fleming L., Sharpe B., Gates P., and Meldrum H. Causes and severity of ischemic stroke in patients with internal carotid artery stenosis. JAMA 283 (2000) 1429-1436
8. Hobson II R.W., Weiss D.G., Fields W.S., Goldstone J., Moore W.S., Towne J.B., et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. N Engl J Med 328 (1993) 221-227
9. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study: Endarterectomy for asymptomatic carotid artery stenosis. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 273 (1995) 1421-1428
10. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363 (2004) 1491-1502
11. Kakkos S.K., Sabetai M., Tegos T., Stevens J., Thomas D., Griffin M., et al. ; for the Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) Study Group. Silent embolic infarcts on computed tomography brain scans and risk of ipsilateral hemispheric events in patients with asymptomatic internal carotid artery stenosis. J Vasc Surg 49 (2009) 902-909
12. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [published correction appears in JAMA 2003;290:197]. JAMA 289 (2003) 2560-2572
13. Psaty B.M., Smith N.L., Siscovick D.S., Koepsell T.D., Weiss N.S., Heckbert S.R., et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 277 (1997) 739-745
14. Neal B., MacMahon S., Chapman N., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 356 (2000) 1955-1964
15. Mosca L., Manson J.E., Sutherland S.E., Langer R.D., Manolio T., and Barrett-Connor E. Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation 96 (1997) 2468-2482
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA 2003;289:178 and JAMA 2004;18:2196]. JAMA 288 (2002) 2981-2997
17. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. ; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
18. Crouse III J.R., Byington R.P., Bond M.G., Espeland M.A., Craven T.E., Sprinkle J.W., et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 75 (1995) 455-459
19. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
20. Collins R., Armitage J., Parish S., Sleight P., and Peto R. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
21. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22 (1991) 983-988
22. Go A.S., Hylek E.M., Chang Y., Phillips K.A., Henault L.E., Capra A.M., et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA 290 (2003) 2685-2692
23. van Walraven C., Hart R.G., Singer D.E., Laupacis A., Connolly S., Petersen P., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288 (2002) 2441-2448
24. Hart R.G., Benavente O., McBride R., and Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131 (1999) 492-501
25. Olsson S.B. Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362 (2003) 1691-1698
26. Albers G.W., and SPORTIF Investigators. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am J Manag Care 10 14 suppl (2004) S462-S469
27. Peto R., Gray R., Collins A., Wheatley K., Hennekens C., Jamrozik K., et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 296 (1988) 313-316
28. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
29. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 351 (1998) 233-241
30. Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Julius S., et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomized trial. Lancet 351 (1998) 1755-1762
31. de Gaetano G. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 357 (2001) 89-95
32. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
33. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 324 (2002) 71-86
34. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 150 (2009) 396-404
35. Goldstein L.B., Adams R., Alberts M.J., Appel L.J., Brass L.M., Bushnell C.D., et al. ; American Heart Association/American Stroke Association Stroke Council; Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; Quality of Care and Outcomes Research Interdisciplinary Working Group; American Academy of Neurology. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: co-sponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 1583-1633
36. Hankey G.J., Jamrozik K., Broadhurst R.J., Forbes S., Burvill P.W., Anderson C.S., and Stewart-Wynne E.G. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 29 (1998) 2491-2500
37. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
38. Algra A., and van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 60 (1996) 197-199
39. Warlow C. Secondary prevention of stroke. Lancet 339 (1992) 724-727
40. van Wijk I., Kappelle L.J., van Gijn J., Koudstaal P.J., Franke C.L., Vermeulen M., et al. ; LiLAC study group. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet 365 (2005) 2098-2104
41. Dutch TIA Study Group. Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke. Stroke 19 (1988) 512-517
42. Farrell B., Godwin J., Richards S., and Warlow C. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
43. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel vs. aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
44. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. ; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
45. Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., et al., CHARISMA Investigators. Clopidogrel and aspirin vs. aspirin alone for the prevention of atherothrombotic events. CHARISMA Investigators. N Engl J Med 354 (2006) 1706-1717
46. Steinhubl S.R., Bhatt D.L., Brennan D.M., Montalescot G., Hankey G.J., Eikelboom J.W., et al. ; CHARISMA Investigators. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 150 (2009) 379-386
47. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study, 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
48. Sacco R.L., Sivenius J., and Diener H.C. Efficacy of aspirin plus extendedrelease dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 62 (2005) 403-408
49. ESPRIT Study Group. Aspirin plus dipyridamole vs. aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 367 (2006) 1665-1673
50. Sacco R.L., Diener H.C., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., et al. ; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359 (2008) 1238-1251
51. Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A., et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359 (2008) 1238-1251
52. Sacco R.L., Adams R., Albers G., Alberts M.J., Benavente O., Furie K., et al., American Heart Association; American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Co-sponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 577-617
53. Albers G.W., Amarenco P., Easton J.D., Sacco R.L., and Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 483S-512S
54. Adams R.J., Albers G., Alberts M.J., Benavente O., Furie K., Goldstein L.B., et al. ; American Heart Association; American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39 (2008) 1647-1652
55. Lennard N., Smith J.L., Gaunt M.E., Abbott R., London N.J.M., Bell P.R.F., and Naylor A.R. A policy of quality control assessment reduces the risk of intra-operative stroke during carotid endarterectomy. Eur J Vasc Endovasc Surg 17 (1999) 234-240
56. Baumgartner R.W. Transcranial color duplex sonography in cerebrovascular disease: a systematic review. Cerebrovasc Dis 16 (2003) 4-13
57. Findlay J.M., Lougheed W.M., Gentili F., Walker P.M., Glynn M.F., and Houle S. Effect of perioperative platelet inhibition on postcarotid endarterectomy mural thrombus formation. Results of a prospective randomized controlled trial using aspirin and dipyridamole in humans. J Neurosurg 63 (1985) 693-698
58. Lindblad B., Persson N.H., Takolander R., and Bergqvist D. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery?. A double-blind, placebo-controlled randomized trial. Stroke 24 (1993) 1125-1128
59. Pratschner T., Kretschmer G., Prager M., Wenzl E., Polterauer P., Ehringer H., et al. Antiplatelet therapy following carotid bifurcation endarterectomy. Evaluation of a controlled clinical trial. Prognostic significance of histologic plaque examination on behalf of survival. Eur J Vasc Surg 4 (1990) 285-289
60. Naylor A.R., Hayes P.D., Allroggen H., Lennard N., Gaunt M.E., Thompson M.M., et al. Reducing the risk of carotid surgery: a 7-year audit of the role of monitoring and quality control assessment. J Vasc Surg 32 (2000) 750-759
61. Lennard N., Smith J.L., Hayes P., Evans D.H., Abbott R.J., London N.J., et al. Transcranial Doppler directed dextran therapy in the prevention of carotid thrombosis: three hour monitoring is as effective as six hours. Eur J Vasc Endovasc Surg 17 (1999) 301-305
62. Laman D.M., Wieneke G.H., Van D.H., and van Huffelen A.C. High embolic rate early after carotid endarterectomy is associated with early cerebrovascular complications, especially in women. J Vasc Surg 36 (2002) 278-284
63. Payne D.A., Jones C.I., Hayes P.D., Thompson M.M., London N.J., Bell P.R., et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 109 (2004) 1476-1481
64. Levi C.R., O'Malley H.M., Fell G., Roberts A.K., Hoare M.C., Royle J.P., et al. Transcranial Doppler detected cerebral microembolism following carotid endarterectomy: high microembolic signal loads predict post-operative cerebral ischaemia. Brain 120 (1997) 621-629
65. Spencer M.P. Transcranial Doppler monitoring and causes of stroke from carotid endarterectomy. Stroke 28 (1997) 685-691
66. Lennard N., Smith J.L., Dumville J., Abbott R., Evans D.H., London N.J., et al. Prevention of post-operative thrombotic stroke after carotid endarterectomy: the role of transcranial Doppler ultrasound. J Vasc Surg 26 (1997) 579-584
67. Cantelmo N.L., Babikian V.L., Samaraweera R.N., Gordon J.K., Pochay V.E., and Winter M.R. Cerebral microembolism and ischaemia changes associated with carotid endarterectomy. J Vasc Surg 27 (1998) 1024-1030
68. Hayes P.D., Box H., Tull S., Bell P.R.F., Goodall A.H., and Naylor A.R. Patients' thromboembolic potential after carotid endarterectomy is related to the platelets' sensitivity to adenosine diphosphate. J Vasc Surg 38 (2003) 1226-1231
69. Aronow H.D., Shishehbor M., Davis D.A., Katzan I.L., Bhatt D.L., Bajzer C.T., et al. Leukocyte count predicts microembolic Doppler signals during carotid stenting: a link between inflammation and embolization. Stroke 36 (2005) 1910-1914
70. Chaturvedi S. Carotid artery stenting for high-risk patients. Neurol Res 24 suppl 1 (2002) S63-S65
71. Markus H.S., Droste D.W., Kaps M., Larrue V., Lees K.R., Siebler M., and Ringelstein E.B. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 111 (2005) 2233-2240
72. Bhatt D.L., Kapadia S.R., Bajzer C.T., Chew D.P., Ziada K.M., Mukherjee D., et al. Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol 13 (2001) 767-771
73. Kapadia S.R., Bajzer C.T., Ziada K.M., Bhatt D.L., Wazni O.M., Silver M.J., et al. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. Stroke 32 (2001) 2328-2332
74. Qureshi A.I., Suri M.F., Ali Z., Kim S.H., Lanzino G., Fessler R.D., et al. Carotid angioplasty and stent placement: A prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery 50 (2002) 466-473
75. Chan A.W., Yadav J.S., Bhatt D.L., Bajzer C.T., Gum P.A., Roffi M., et al. Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting. Am J Cardiol 95 (2005) 791-795
76. Kopp C.W., Steiner S., Nasel C., Seidinger D., Mlekusch I., Lang W., et al. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting. Stroke 34 (2003) 2560-2567
77. Wholey M.H., Wholey M.H., Eles G., Toursakissian B., Bailey S., Jarmolowski C., and Tan W.A. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting. J Endovasc Ther 10 (2003) 33-41
78. Timaran C.H., Veith F.J., Rosero E.B., Modrall J.G., Valentine R.J., and Clagett G.P. Intracranial hemorrhage after carotid endarterectomy and carotid stenting in the United States in 2005. J Vasc Surg 49 (2009) 623-628
79. CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
80. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., and Topol E.J. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 288 (2002) 2411-2420
81. Kramer J., Abraham J., Teven C.M., and Jones P.A. Role of antiplatelets in carotid artery stenting. Stroke 38 (2007) 14 author reply 15
82. Gotoh F., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., Otomo E., et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral ischemia. J Stroke Cerebrovasc Dis 9 (2000) 147-157
83. Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 6 (2005) 33-40
84. Pletal (cilostazol) tablets [prescription information] (2005), Otsuka America Pharmaceutical, Inc, Rockville, Md
85. Biondi-Zoccai G.G., Lotrionte M., Anselmino M., Moretti C., Agostoni P., Testa L., et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 155 (2008) 1081-1089
86. Soga Y., Yokoi H., Kawasaki T., Nakashima H., Tsurugida M., Hikichi Y., and Nobuyoshi M. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. J Am Coll Cardiol 53 (2009) 48-53